
Tirzepatide
What it is?
Tirzepatide is a dual incretin receptor agonist studied for GLP-1 and GIP pathway engagement in metabolic regulation. It is positioned for protocols targeting glycaemic control, appetite signalling, and body-weight reduction endpoints through coordinated endocrine modulation.
Dripfy Advantage
- Receptor engagement: Activates GLP-1 and GIP receptors, supporting multi-pathway incretin signalling relevant to metabolic control.
- Appetite & satiety signalling: Associated with central mechanisms that reduce hunger drive and enhance satiety-related behavioural endpoints.
- Glucose–insulin dynamics: Supports improved insulin sensitivity markers and glucose regulation endpoints in structured metabolic models.
- Energy balance modulation: Positioned to influence energy intake–expenditure balance, supporting fat-mass reduction endpoints over time.
Clinical Applications & Therapeutic Potential
- Weight-management endpoints: Potential support for body-weight reduction and fat-mass shift markers in controlled protocols.
- Metabolic health markers: Potential improvements in glycaemic control endpoints and insulin sensitivity markers (context-dependent).
- Cardiometabolic profile support: Potential downstream benefits across lipid-related markers and broader cardiometabolic risk parameters.
- Lean-mass preservation focus: Frequently positioned within protocols that track fat-to-lean ratio endpoints during weight-reduction phases.
Composition & Formulation
- Class: Dual incretin receptor agonist peptide (GIP/GLP-1 pathway class)
- Format: Lyophilized peptide for research use
Clinical Applications & Therapeutic Potential
Composition & Formulation
Choose options

Tirzepatide
Sale price£350.00
Regular price